FDA approves Keytruda plus Lenvima for advanced kidney cancer
Combination treatment reduced the risk of disease progression or death by 61% versus Sutent
Read Moreby Lucy Parsons | Aug 12, 2021 | News | 0
Combination treatment reduced the risk of disease progression or death by 61% versus Sutent
Read Moreby Lucy Parsons | Sep 21, 2020 | News | 0
Data shows a range of responses in different tumours
Read Moreby Selina McKee | Jul 9, 2020 | News | 0
Regulators rejected accelerated approval as Roche’s combination for the same patient population made it over the line first
Read Moreby Anna Smith | Apr 9, 2019 | News | 0
Also mentioned were Eisai and MSD’s Lenvima and UCB’s Cimzia.
Read Moreby Anna Smith | Dec 21, 2018 | News | 0
The National Institute for Health and Care excellence (NICE) has recommended Eisai and MSD’s Lenvima, a potentially life-extending treatment for adults with advanced liver cancer.
Read Moreby Selina McKee | Nov 9, 2018 | News | 0
NICE has issued draft guidelines backing use of Eisai/MSD’s Lenvima on the NHS in England and Wales as an option for a type of untreated, advanced liver cancer.
Read Moreby Selina McKee | Aug 24, 2018 | News | 0
Eisai and MSD’s Lenvima has won approval in the EU as a first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Read Moreby Selina McKee | Aug 17, 2018 | News | 0
Eisai and MSD’s Lenvima (lenvatinib) has been approved in the US for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
Read Moreby Selina McKee | Jan 10, 2018 | News | 0
A combination therapy being developed by MSD and Eisai for kidney cancer has been awarded Breakthrough Designation in the US.
Read Moreby Selina McKee | Oct 23, 2017 | News | 0
NHS treatment cost regulators have published draft guidelines rejecting funding for Eisai’s Lenvima and Bayer’s Nexavar for treating certain patients with thyroid cancer.
Read Moreby Selina McKee | Jul 26, 2017 | News | 0
Eisai has filed its anticancer drug lenvatinib for liver cancer on both sides of the Atlantic as it seeks to expand the drug’s list of approved uses.
Read Moreby Selina McKee | Jan 25, 2017 | News | 0
A late-stage trial assessing Eisai’s cancer drug Lenvima for hepatocellular carcinoma (HCC) has achieved its primary endpoint, pushing the drug closer to being filed for approval in this setting.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
